Video

There Are Multiple Dynamic Biomarkers for Bladder Cancer

Author(s):

Padmanee Sharma, M.D., Ph.D.

While there are a few common and well-known checkpoints for bladder cancer, there are also many more than PD-1, PD-L1 and CTLA-4.

When it comes to biomarkers used to determine treatment strategy in bladder cancer, there is more than PD-1, PD-L1 and CTLA-4, says Padmanee Sharma, M.D., Ph.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

Researchers have not yet examined or reached a full understanding of all the possible checkpoints, especially since the targets — like the immune response in general – are very dynamic and change over time.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Related Content
Graphic that reads "FDA APPROVED" resembling a stamp of approval
June 12th 2025

FDA Approves UGN-102 For Some With Bladder Cancer

Bridget Hoyt
The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq: © stock.adobe.com
May 30th 2025

Additive Antihistamines May Improve Metastatic Bladder Cancer Outcomes

Alex Biese
Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Aidixi plus toripalimab met study end points for patients with HER2-expressing urothelial carcinoma: © stock.adobe.com.
May 14th 2025

Aidixi Combination Therapy Improves Survival in Urothelial Carcinoma

Spencer Feldman
Aidixi plus toripalimab met progression-free and overall survival study end points versus chemo for patients with HER2-expressing urothelial carcinoma.
Illustration of bladder.
May 13th 2025

Custom-Made Vaccine Combo Proves Effective in Bladder Cancer

Ryan Scott
Treatment with a custom-made vaccine combination was found to be safe and feasible for patients with bladder cancer, eliciting a strong immune response.